✦ LIBER ✦

Melperone is ineffective in treating Parkinson's disease psychosis

✍ Scribed by Joseph H. Friedman

Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 689 KB
Volume: 27
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.24942

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Psychosis in Parkinson's disease

✍ Werner Poewe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and

Clozapine for psychosis in Parkinson's d

Clozapine for psychosis in Parkinson's disease

✍ Dr. Ronald F. Pfeiffer; Jasbir Kang; Benjamin Graber; Ruth Hofman; James Wilson 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because

Reply: Rebound psychosis in Parkinson's

Reply: Rebound psychosis in Parkinson's disease

✍ Hubert H. Fernandez; Michael S. Okun 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB 👁 1 views

## Abstract The original letter to which this reply refers was published in __Movement__ DisordersMov Disord (2005) 20 (4) 515.

Clozapine prevents recurrence of psychos

Clozapine prevents recurrence of psychosis in Parkinson's disease

✍ Dr. Stewart A. Factor; Diane Brown 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 1012 KB

## Abstract Psychosis secondary to dopaminergic therapy can limit the ability to manage motor symptoms of advanced Parkinson's disease (PD). We report the results of an open label 3‐month trial that evaluated the antipsychotic effects of clozapine in eight PD patients with drug‐induced psychosis. R

The neurochemical mechanism of rebound p

The neurochemical mechanism of rebound psychosis in Parkinson's disease

✍ Spiridon Papapetropoulos; Deborah C. Mash 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB 👁 1 views

## Abstract A reply to this letter has been published in __Movement__ DisordersMov Disord (2005) 20 (4) 515.

Scales to assess psychosis in Parkinson'

Scales to assess psychosis in Parkinson's disease: Critique and recommendations

✍ Hubert H. Fernandez; Dag Aarsland; Gilles Fénelon; Joseph H. Friedman; Laura Mar 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 1 views

## Abstract Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer‐reviewed rating psychosis scales used in PD psychosis st